

## Sample patent analysis

S.No.	Patent/ Publication No.	Patent focus (compounds, compositions, or etc.)	Compounds/ Active ingredients in compositions	Function of the compounds	Disease/disorder to be treated	Admini stration (oral, injection, or etc.)	Dolcera summary
1	US 7098029B1	Food and beverage products	Peptide (C-terminal growth hormone fragment)	Stimulates the activity of hormone-sensitive lipase, inhibits acetyl CoA carboxylase, reduce lipogenic activity, and stimulate lipolysis	Obesity	Oral	Food or beverage comprises a transgene plant or parts, which comprise a nucleic acid molecule, the nucleic acid molecule encoding a C-terminal growth hormone fragment which has the ability to modulate lipid metabolism
2	US 6596742B1	Pharmaceutical composition, and compounds	Substituted 3-phenyl-5-alkoxy -1,3,4-oxadiazol-2-ones	Inhibits hormone-sensitive lipase	Non-insulin-dependent diabetes mellitus, and diabetic syndrome	N/A	Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones to treat metabolic disorder, which show inhibitory effect on hormone sensitive lipase
3	US2007 0010423A1	Pharmaceutical composition	Baloglitazone and one or more other anti-diabetic compounds, anti-diabetic compound is selected from amongst insulin secretagogues, insulin sensitizers, potassium channel openers, glucagons antagonists, protein tyrosine phosphatase inhibitors, glucokinase activators, RXR agonists, <i>hormone sensitive lipase inhibitors</i> , glycogen synthase kinase-3 inhibitors, glycogen phosphorylase inhibitors, glucose uptake modulators and lipid lowering compounds	Inhibits hormone sensitive lipase (in case of hormone sensitive lipase inhibitors as anti-diabetic)	Treat type 2 diabetes, dyslipidemia, hyperglycemia, hyperinsulinemia, insulin resistance, obesity, cardiovascular complications, atherosclerosis, hypertension, impaired glucose tolerance, impaired fasting glucose level, increased plasma levels of free fatty acids, increased levels of plasma triglycerides, and increased plasma levels of very low density lipoproteins (VLDL)	N/A	A pharmaceutical composition comprising balaglitazone and one or more other anti-diabetic compounds. The anti-diabetic compounds may be hormone sensitive lipase inhibitors.
4	US2006 0160819A1	Pharmaceutical compositions and compounds	Substitued piperazine carbamates	Inhibits of hormone sensitive lipase	Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atherosclerosis, hypertension, abnormalities of lipoprotein metabolism	Oral, nasal, transdermal, pulmonal, or parenteral	Novel piperazine carbamates and their compositions to treat or prevent diseases related to hormone sensitive lipase. Piperazine carbamates inhibit hormone sensitive lipase activity
5	US2006 0148860A1	Pharmaceutical compositions, and compounds	Substitued p-phenyl carbamates	Inhibits the lipolytic activity of hormone sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters	Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atherosclerosis, hypertension, abnormalities of lipoprotein metabolism	Oral, nasal, transdermal, pulmonal, or parenteral	Substitued p-phenyl carbamates to treat or prevent hormone sensitive lipase related diseases. Substitued p-phenyl carbamates decrease the activity of hormone sensitive lipase
6	US2006 0148799A1	Pharmaceutical compositions, and compounds	Substitued p-phenyl carbamates	Inhibits hormone sensitive lipase	Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atherosclerosis, hypertension, abnormalities of lipoprotein metabolism	Oral, nasal, transdermal, pulmonal, or parenteral	Substitued p-phenyl carbamates to treat or prevent diseases related to hormone sensitive lipase by lowering the activity of the hormone sensitive lipase
7	US2005 0271755A1	Botanical compositions	Coumarin derivatives: 6,7-dihydroxycoumarin (esculetin), and esculetin like compounds	Modulates biological activity of at least one enzyme among the group consisting of pancreatic lipase (PL), lipoprotein	Obesity, cardiovascular disease, and diabetes	N/A	Botanical compositions to control of lipid accumulation and metabolism in mammals thereby providing prevention or treatment of obesity, diabetes, and heart disease

				lipase (LPL), and hormone sensitive lipase (HSL)			
8	US2005 0197348A1	Pharmaceutical composition, and compounds	Indazole derivatives	Inhibits hormone sensitive lipase	Insulin resistance, diabetes mellitus, dyslipidemias, and metabolic syndrome	N/A	Indazole derivatives to treat or prevent disorders of fatty acid metabolism and glucose utilization disorders, which inhibit hormone sensitive lipase